A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

Crux, the first no-fee benefits platform working directly with pharmaceutical companies and employers of all sizes to expand transparent and affordable access to transformative FDA-approved ...

In this week’s edition of InnovationRx, Medline’s blockbuster IPO, Fred Moll’s surgical robotics investments, Forbes' ...

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

The market for GLP-1 drugs is projected to reach $180 billion in 2034, according to Morningstar Equity Research. Current ...

The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...